Sector consensus Takeda Pharmaceutical Company Limited

Equities

Market Closed - Japan Exchange Other stock markets 02:30:00 2025-07-07 EDT			5-day change	1st Jan Change
4,412.00 ^JPY	-0.63%		+1.05%	+5.52%

11:03am	US FDA approves KalVista's oral swelling disorder drug, shares rise	RE
06-30	Takeda Pharmaceutical Company Limited Announces U.S. FDA Approval of Gammard Liquid Immunoglobulin Therapy with Low Immunoglobulin A Content	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Average Target P.	Ecart obj. / dr	Nbr of analysts
TAKEDA PHARMACEUTICAL COMPANY LIMITED		JP¥4,946.56	+11.41%	16
ELI LILLY AND COMPANY		US$951.98	+21.94%	27
JOHNSON & JOHNSON		US$169.23	+8.47%	23
ABBVIE INC.		US$209.12	+10.48%	27
NOVO NORDISK A/S		DKK 645.23	+42.97%	22
ROCHE HOLDING AG		CHF 302.68	+16.41%	20
NOVARTIS AG	-	CHF 119.55	-3.35%	19
ASTRAZENECA PLC		GBX 183.34	+30.02%	20
MERCK & CO., INC.		US$101.79	+25.77%	24
AMGEN INC.		US$314.27	+5.37%	28
PFIZER, INC.		US$29.06	+14.48%	23
GILEAD SCIENCES, INC.		US$116.77	+4.49%	26
SANOFI		€113.34	+36.08%	23
VERTEX PHARMACEUTICALS INCORPORATED		US$499.87	+8.76%	28
BRISTOL-MYERS SQUIBB COMPANY		US$57.1	+21.69%	22
CHUGAI PHARMACEUTICAL CO., LTD.		JP¥8,353.57	+17.24%	14
GSK PLC		GBX 16.61	+18.22%	19
JIANGSU HENGRUI MEDICINE CO., LTD.		CN¥65.39	+22.78%	18
HALEON PLC		GBX 4.247	+12.39%	17
Average		905.25	+17.14%	22
Weighted average by Cap.		600.76	+17.95%	23